You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Stryker Corporation increased its board from 11 to 12 directors and elected James E. Davis effective January 1, 2027. Davis has served as Quest Diagnostics’ CEO and President since November 2022 and Chairman since April 2023.
Stryker Corporation established an automatic shelf to sell common and preferred stock, debt securities, warrants and other securities in future offerings. Proceeds may fund working capital, acquisitions, debt repayment or refinancing, stock repurchases and other business opportunities.
Stryker Corporation reported three-month 2026 sales growth of 7.7%, net earnings of $753 and diluted EPS of $1.96, while a $293 Peripheral Vascular goodwill impairment reduced operating margin to 15.9%.
Stryker reported third-quarter organic sales growth of 7.7% and adjusted EPS of $3.52, up 10.3%, citing a hip-and-knee market slowdown and peripheral vascular supply constraints. It revised full-year guidance to 6.5% to 7% organic sales growth and adjusted net EPS of $14.80 to $14.90.
Stryker reported third-quarter 2026 organic sales growth of 7.7% and adjusted EPS of $3.52, up 10.3%, but missed expectations. Its board added $3.0 billion to repurchases; guidance is 6.5% to 7.0% organic sales growth and adjusted EPS of $14.80 to $14.90.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted effective income tax rate non-GAAP | 16% | Three Months 2026 filing | — |
| adjusted gross profit non-GAAP | 4.27B | Three Months 2026 filing | — |
| adjusted gross profit percent net sales non-GAAP | 65.4% | Three Months 2026 filing | — |
| adjusted income taxes non-GAAP | 258M | Three Months 2026 filing | — |
| adjusted net earnings non-GAAP | $1.36B | three months 2026 filing | — |
| adjusted net earnings per diluted share non-GAAP | $3.52 | three months 2026 filing | — |
|
|
|||
| adjusted net earnings percent net sales non-GAAP | 20.8% | Three Months 2026 filing | — |
| adjusted operating income non-GAAP | 1.71B | Three Months 2026 filing | — |
| adjusted operating income margin non-GAAP | 26.2% | three months 2026 filing | — |
| adjusted other income (expense), net non-GAAP | -91M | Three Months 2026 filing | — |
| adjusted other income (expense), net percent net sales non-GAAP | -1.4% | Three Months 2026 filing | — |
| adjusted research, development and engineering expenses non-GAAP | 417M | Three Months 2026 filing | — |
| adjusted research, development and engineering expenses percent net sales non-GAAP | 6.4% | Three Months 2026 filing | — |
| adjusted selling, general and administrative expenses non-GAAP | 2.14B | Three Months 2026 filing | — |
| adjusted selling, general and administrative expenses percent net sales non-GAAP | 32.8% | Three Months 2026 filing | — |
| percentage organic sales growth non-GAAP | 8.9% | three months 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SYK
this stock
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
|
EW
Edwards Lifesciences Corp
|
$61.61B | +25.7% | +11.5% | 60.5 | 1.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Stryker Corporation increased its board from 11 to 12 directors and elected James E. Davis effective January 1, 2027. Davis has served as Quest Diagnostics’ CEO and President since November 2022 and Chairman since April 2023.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SYK | -5.0% | +5.1% | -1.1% | +6.1% | -11.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -7.6% | +6.2% | -1.6% | +6.3% | -22.5% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
